Chemomab Therapeutics (CMMB) Enterprise Value (2021 - 2026)

Chemomab Therapeutics (CMMB) has reported Enterprise Value for 6 consecutive years, with $5.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value fell 59.84% year-over-year to $5.0 million; the trailing twelve-month figure through Jun 2026 stood at $5.0 million (down 59.84% YoY), and the FY2025 full-year result was $1.5 million, down 92.44% from the prior year.
• Enterprise Value climbed to $5.0 million in Q2 2026 per CMMB's latest filing, from $3.2 million in the prior quarter.
• Across five years, Enterprise Value topped out at $19.9 million in Q4 2024 and bottomed at -$18.1 million in Q4 2023.
• Historically, Enterprise Value has averaged -$2.5 million across 5 years, with a median of -$2.4 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Enterprise Value slumped 433.4% in 2023, then surged 694.5% in 2025.
• Over 5 years, Enterprise Value stood at -$4.4 million in 2022, then tumbled by 311.91% to -$18.1 million in 2023, then surged by 209.78% to $19.9 million in 2024, then tumbled by 92.44% to $1.5 million in 2025, then soared by 230.69% to $5.0 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $5.0 million, $3.2 million, and $1.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.